Related Experiment Video
Updated: May 7, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Long-term impact of 10-valent pneumococcal conjugate vaccine among children <5 years, Uganda, 2014-2021
Mercy Wendy Wanyana1, Richard Migisha1, Patrick King1
1Uganda Public Health Fellowship Program, Uganda National Institute of Public Health, Kampala, Uganda.
Insights
Pneumonia admissions and deaths in Ugandan children under 5 declined after pneumococcal conjugate vaccine (PCV) introduction. However, progress is insufficient to meet global targets, necessitating intervention reviews.
Area of Science:
- Pediatrics
- Infectious Diseases
- Public Health
Background:
- Pneumonia is a leading cause of mortality in children under 5 in Uganda.
- The pneumococcal conjugate vaccine (PCV) was introduced into routine immunization in 2014.
- Long-term impacts of PCV on pediatric pneumonia in Uganda require further investigation.
Purpose of the Study:
- To describe trends and spatial distribution of pneumonia hospital admissions and mortality in Ugandan children under 5 from 2014-2021.
- To assess the impact of PCV introduction on pneumonia outcomes.
- To evaluate progress towards global targets for pneumonia reduction.
Main Methods:
- Analysis of secondary data from Uganda's District Health Information System version 2 (2014-2021).
- Calculation of pneumonia admission proportions, case-fatality rates (CFRs), and mortality rates per 100,000 children under 5.
- Application of the Mann-Kendall Test to determine trend significance.
Main Results:
- Over 667,000 pneumonia admissions and 11,692 deaths were recorded (2014-2021).
- Significant declines observed in pneumonia admissions (31% to 15%), mortality rates (24/100,000 to 14/100,000), and CFR (0.57% to 0.24%) post-PCV introduction.
- Persistent high admission rates in Kotido and high mortality rates in Kasese districts were noted.
Conclusions:
- Pneumonia burden decreased in Ugandan children under 5 following PCV implementation.
- Current trends suggest Uganda may not achieve the 2025 GAPPD targets.
- Review of interventions and identification of implementation gaps are crucial to accelerate progress.
Abstract:
Pneumonia is the second leading cause of hospital admissions and deaths among children <5 years in Uganda. In 2014, Uganda officially rolled out the introduction of the pneumococcal conjugate vaccine (PCV) into routine immunization schedule. However, little is known about the long-term impact of PCV on pneumonia admissions and deaths. In this study, we described the trends and spatial distribution of pneumonia hospital admissions and mortality among children <5 years in Uganda, 2014-2021. We analysed secondary data on pneumonia admissions and deaths from the District Health Information System version 2 during 2014-2021. The proportion of pneumonia cases admitted and case-fatality rates (CFRs) for children <5 years were calculated for children <5 years presenting at the outpatient department. At national, regional, and district levels, pneumonia mortality rates were calculated per 100,000 children <5 years. The Mann-Kendall Test was used to assess trend significance. We found 667,122 pneumonia admissions and 11,692 (2%) deaths during 2014-2021. The overall proportion of pneumonia cases admitted among children <5 years was 22%. The overall CFR was 0.39%, and the overall pneumonia mortality rate among children <5 years was 19 deaths per 100,000. From 2014 to 2021, there were declines in the proportion of pneumonia cases admitted (31% to 15%; p = 0.051), mortality rates (24/100,000 to 14 per 100,000; p = 0.019), and CFR (0.57% to 0.24%; p = 0.019), concomitant with increasing PCV coverage. Kotido District had a persistently high proportion of pneumonia cases that were admitted (>30%) every year while Kasese District had persistently high mortality rates (68-150 deaths per 100,000 children <5 years). Pneumonia admissions, mortality, and case fatality among children <5 years declined during 2013-2021 in Uganda after the introduction of PCV. However, with these trends it is unlikely that Uganda will meet the 2025 GAPPD targets. There is need to review implementation of existing interventions and identify gaps in order to highlight priority actions to further accelerate declines.
More Related Videos
Related Concept Videos
Vaccinations
Lung Capacity

